# CENTERA PMCF: Post-Market Follow-up of the CENTERA Transcatheter Heart Valve System

> **NCT03699345** · — · COMPLETED · sponsor: **Edwards Lifesciences** · enrollment: 87 (actual)

## Conditions studied

- Aortic Valve Stenosis

## Interventions

- **DEVICE:** Transcatheter Aortic Valve Replacement (TAVR)

## Key facts

- **NCT ID:** NCT03699345
- **Lead sponsor:** Edwards Lifesciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2019-08-14
- **Final completion:** 2024-08-20
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03699345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03699345, "CENTERA PMCF: Post-Market Follow-up of the CENTERA Transcatheter Heart Valve System". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03699345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*